Hansa Medical AB to change name to Hansa Biopharma AB
Lund, Sweden, December 20, 2018-Hansa Medical AB (publ) (Nasdaq Stockholm:HMED) (“Hansa Medical” or the “Company”), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that the name change resolutions approved at an Extraordinary General Meeting ("EGM") held on December 4, 2018, have been approved by the ‘Bolagsverket’ in Sweden.
The name change will be implemented in the next days and weeks and the Company stock ticker symbol has changed from “HMED” to “HNSA”.
The information was submitted for publication, through the agency of the contact person set out below, at 2:15 pm CET on December 20, 2018.
For further information, please contact:
Company:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)
Mobile: +46 707 175477
E-mail: emanuel.bjorne@hansamedical.com
Swedish Investor and Media Relations:
Cord Communications
Mikael Widell
+46 70-311 99 60
U.K. Investor and Media Relations
FTI Consulting
Simon Conway/ Stephanie Cuthbert
+44 (0)20 3727 1000
U.S. Investor and Media Relations:
Argot Partners
Stephanie Marks/ David Rosen (media)
+1 212 600 1902
About Hansa Medical
Hansa Medical (NASDAQ Stockholm:HNSA) is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications. Hansa also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, the Company is developing novel immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden.
Tags: